Charles W Newhall III
CIK 1005544 · last filed 2026-02-25
Charles W Newhall III is a corporate insider who has filed 129 SEC Form 4 insider transactions across 16 companies since 2007. The most recent filing, for SUPN, was dated Feb 25, 2026. Across all open-market trades the lifetime net is −$8.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $327.8M across reported positions. 43 SEC filings were submitted jointly with Mark W Perry.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FIO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BALTIMORE, MD 21202
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SUPN | Director | 6,365,369 | $41.39 | $263.46M | $20.00M | 32 | 2026-02-25 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | Director | 289 | — | — | $0 | 4 | 2015-07-10 |
| WDAY | 10%+ Owner | — | $208.71 | — | $0 | 1 | 2012-10-18 |
| FUSION-IO, INC. (FIO) Delisted | 10%+ Owner | 9,039,445 | — | — | -$40.98M | 15 | 2012-09-06 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | 10%+ Owner | 1,639,218 | — | — | $5.00M | 1 | 2012-08-02 |
| INNERWORKINGS INC (INWK) Delisted | 10%+ Owner | 4,529,190 | — | — | -$12.62M | 8 | 2012-03-30 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 1,066,029 | $14.49 | $15.45M | $6.40M | 3 | 2012-03-09 |
| ECHO | 10%+ Owner | 4,095 | $85.75 | $351.1K | $0 | 1 | 2012-03-01 |
| VG | 10%+ Owner | 4,558,701 | $12.61 | $57.46M | $0 | 1 | 2011-03-15 |
| Financial Engines, Inc. (FNGN) Delisted | 10%+ Owner | 2,808,848 | — | — | $0 | 2 | 2010-09-01 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | — | $18.62 | — | $0 | 1 | 2009-11-03 |
| INHIBITEX, INC. (INHX) Delisted | 10%+ Owner | 1,941,407 | — | — | $3.00M | 1 | 2009-10-30 |
| Data Domain, Inc. (DDUP) Delisted | 10%+ Owner | 1,004,916 | — | — | $0 | 2 | 2009-07-10 |
| PHARMOS CORP (PARS) Delisted | Director | 10,882 | — | — | $0 | 7 | 2009-01-16 |
| TNDM | 10%+ Owner | 386,220 | $16.95 | $6.55M | $0 | 1 | 2008-09-24 |
| DZS INC. (ZHNE) Delisted | 10%+ Owner | 1,788,067 | — | — | $10.44M | 31 | 2008-03-10 |
Recent Filings
129 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-25 | SUPN | Mixed | +4,475 | $0 | EDGAR |
| 2026-02-20 | SUPN | Grant (A) | — | $0 | EDGAR |
| 2025-11-24 | SUPN | Exer (M) | +15,000 | $194.7K | EDGAR |
| 2025-10-10 | SUPN | Sell (S) | −25,000 | -$1.27M | EDGAR |
| 2025-10-09 | SUPN | Notice (144) | −25,000 | -$1.20M | EDGAR |
| 2025-08-29 | SUPN | Sell (S) | −3,588 | -$161.5K | EDGAR |
| 2025-08-27 | SUPN | Sell (S) | −1,000 | -$45.0K | EDGAR |
| 2025-08-26 | SUPN | Sell (S) | −1,412 | -$63.5K | EDGAR |
| 2025-08-25 | SUPN | Notice (144) | −4,588 | -$205.9K | EDGAR |
| 2025-08-22 | SUPN | Notice (144) | −1,412 | -$61.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.